Furthermore, we found a progressive shift of p-GSK-3βSer9 to the nucleus associated with increase in p-β-cateninSer552 during progression from hyperplasia through dysplasia to carcinoma confirming the inactivation of GSK-3β. This evidence concerns the gene GSK3B and carcinoma.